top of page

Scott M. Rocklage, PhD

Board Chairman

Scott M. Rocklage, PhD joined 5AM Ventures in 2003 as a Venture Partner, became a Managing Partner in 2004 and transitioned to Founding Partner in 2017. Dr. Rocklage has over three decades of healthcare management experience with strategic leadership responsibilities that led to FDA approval of three U.S. New Drug Applications (Omniscan™, Teslascan® and Cubicin®). He has served as Chairman and CEO of Cubist Pharmaceuticals, President and CEO of Nycomed Salutar and has also held R&D positions at Salutar and Catalytica. Dr. Rocklage formerly served as Board Chairman of Relypsa (acquired by Vifor Pharma), Novira (acquired by J&J), Aprea (NASDAQ: APRE), Cidara (NASDAQ: CDTX), Albamunity and Halio. He currently serves as Board Chairman of Expansion and is a Board member at NodThera and Nouscom. He was formerly Executive Chairman of Ilypsa (acquired by Amgen), Miikana (acquired by EntreMed) and Semprus (acquired by Teleflex). Dr. Rocklage received his B.S. in Chemistry from the University of California, Berkeley and his Ph.D. in Chemistry from MIT where he conducted research in the laboratory of Richard R. Schrock (Nobel Prize in Chemistry in 2005). He is an inventor or co-inventor of over 35 U.S. patents and has produced more than 100 peer-reviewed publications. Dr. Rocklage is based in the Boston, MA office.

bottom of page